Targeting the Undruggable
SyntheX is using the power of genetics and synthetic biology to build the next generation of drug discovery engines.
We discover and develop therapeutics for conventionally undruggable targets using functional selection to target currently inaccessible mechanisms of action.
OUR TECHNOLOGY
We have developed ToRPPIDO to discover disruptors of protein-protein interactions, and ToRNeDO to discover molecular glue-based functional protein degraders using a pre-specified E3 ligase and a neosubstrate of interest.
Our platforms can use canonical small molecule HTS approaches or select from our proprietary genetically encoded peptide and rigidified scaffold libraries of billions of compounds.
OUR PIPELINE
Our internal programs are focused on oncology. We select drug targets based on oncogene addiction and synthetic lethality and target them in orthogonal ways.
THE FOUNDING TEAM
Maria Soloveychik
Co-Founder & Chief Executive Officer
Charly Chahwan
Co-Founder & Chief Science Officer
ADVISORY BOARD
Robert Williamson
Senior Advisor
Leonard Post, PhD
SAB
Andrew Perlman, MD, PhD
SAB
SAB
Tomi Sawyer, PhD
OUR INVESTORS
INCUBATOR & ACCELERATOR SUPPORT
OPEN POSITIONS
Imagine. Design. Build. Create.
Are you an enthusiastic scientist who's excited about using synthetic biology to advance drug discovery?
We are always keeping an eye out for talented members to join our growing team.
RESEARCH ASSISTANTS (BS or MS):
-
Molecular Biology
-
Biochemistry
-
Cell Biology
-
Peptide Chemistry
RESEARCH SCIENTISTS (PhD+):
-
Proteomics
-
Enzyme Engineering
-
Microbial Genetics
-
Biochemistry
-
Cancer Cell Biology
GET IN TOUCH
